Disseminated Intravascular Coagulation (DIC)

01Pathophysiology

DIC is never a primary disease. It is always a secondary phenomenon triggered by an underlying condition that causes widespread, uncontrolled activation of the coagulation cascade. Understanding this principle is fundamental because every exam question on DIC will embed the trigger condition within the vignette.

The initiating event involves the release of tissue factor (TF) into the circulation. In sepsis, bacterial endotoxins and inflammatory cytokines (TNF-alpha, IL-1, IL-6) stimulate monocytes and damaged endothelial cells to express tissue factor. In obstetric emergencies, placental tissue and amniotic fluid are rich sources of tissue factor-like procoagulant material. In malignancy, tumor cells directly express tissue factor and cancer procoagulants. Regardless of the trigger, the downstream pathway converges on the same result: tissue factor binds Factor VIIa, generating thrombin on a systemic scale.

This massive thrombin generation drives two simultaneous and paradoxical processes. First, thrombin converts fibrinogen to fibrin, forming microthrombi that deposit throughout the microvasculature. These fibrin strands obstruct small vessels, causing ischemic end-organ damage to the kidneys, brain, lungs, liver, and skin. Red blood cells are sheared as they pass through these fibrin meshworks, producing the schistocytes (fragmented red cells) seen on the peripheral smear, which is why DIC is classified among the microangiopathic hemolytic anemias (MAHAs).

Second, the body's natural fibrinolytic system activates in response. Plasmin breaks down the deposited fibrin, generating fibrin degradation products (FDPs) and D-dimers. These FDPs themselves are anticoagulant: they interfere with fibrin polymerization and impair platelet function, worsening the bleeding tendency.

The critical concept is consumption. As clotting factors, fibrinogen, and platelets are consumed in the formation of countless microthrombi, the patient runs out of hemostatic resources. This is why DIC produces the seemingly contradictory picture of clotting and bleeding at the same time. The thrombocytopenia is from platelet consumption, the prolonged PT/aPTT is from clotting factor depletion, and the low fibrinogen reflects its conversion to fibrin and its degradation by plasmin.

Additionally, the natural anticoagulant pathways (antithrombin III, protein C, protein S) are rapidly depleted during DIC, removing the brakes on coagulation and creating a self-perpetuating cycle. This is why treating the underlying cause is paramount: without removing the trigger, the cycle cannot be broken.

02Classification and Clinical Manifestation

DIC presents in two distinct clinical patterns. The distinction matters because the predominant features and management differ.

In acute DIC, the consumption outpaces production, so the patient bleeds. In chronic DIC, the liver and marrow can partially keep up with consumption, so thrombosis predominates and lab values may be only mildly deranged.

Purpura fulminans deserves emphasis. It is a severe, life-threatening manifestation of acute DIC characterized by rapidly progressive hemorrhagic necrosis of the skin, typically affecting the extremities, and is associated with meningococcemia (Neisseria meningitidis sepsis) in pediatric populations and protein C deficiency states. When a vignette describes a child with fever, shock, and spreading purpuric skin lesions, the combination should trigger immediate recognition of DIC secondary to meningococcal sepsis.

03Diagnostic Workup

There is no single confirmatory test for DIC. The diagnosis is made by recognizing the combination of clinical context plus a characteristic laboratory pattern. This is a crucial point for exam purposes: the question will never ask for a single gold standard test. Instead, it will present a constellation of labs and ask you to identify the diagnosis.

The best initial approach is to order a coagulation panel (PT, aPTT, platelet count, fibrinogen, D-dimer) and a peripheral blood smear. The classic DIC lab profile is the simultaneous presence of:

1. Thrombocytopenia (or a rapidly declining platelet count, which is even more telling than a single low value)

2. Prolonged PT and aPTT (both pathways affected because all factors are consumed)

3. Low fibrinogen (this is a distinguishing feature; most other coagulopathies do not lower fibrinogen)

4. Elevated D-dimer (the most sensitive single marker; a normal D-dimer essentially rules out DIC)

5. Schistocytes on peripheral smear (confirms microvascular fibrin deposition)

The International Society on Thrombosis and Haemostasis (ISTH) DIC Scoring System is the validated diagnostic tool. It uses a point system based on platelet count, D-dimer/FDP elevation, prolonged PT, and fibrinogen level. A score of $\ge 5\backslash geq\; 5$ confirms overt DIC. This scoring system is worth knowing conceptually: it reinforces that DIC is diagnosed by the aggregate pattern, not a single test.

A point about fibrinogen that frequently appears on exams: fibrinogen is an acute-phase reactant, so in conditions like sepsis it may be elevated at baseline. A "normal" fibrinogen in a septic, critically ill patient may actually represent a significant drop from an elevated baseline and should still raise suspicion for DIC. Serial measurements showing a declining trend are more informative than a single value.

The mixing study result in DIC is also testable. When you mix the patient's plasma 1:1 with normal plasma, the PT/aPTT typically does not correct. This is because FDPs act as circulating inhibitors of coagulation. This contrasts with a pure factor deficiency (e.g., hemophilia), where the mixing study corrects.

04Management and Treatment

The single highest-yield management principle is: treat the underlying cause. This is the answer in most exam scenarios. DIC cannot resolve as long as the trigger persists. In sepsis, this means aggressive antibiotics and source control. In placental abruption or amniotic fluid embolism, this means delivery. In APL, this means starting ATRA immediately. Every other intervention is supportive and will fail if the underlying cause is not addressed.

Supportive transfusion therapy is indicated when the patient is actively bleeding or at high risk for hemorrhage. The approach follows a logical hierarchy:

• Cryoprecipitate is the first-line product for fibrinogen replacement because it is concentrated: it contains fibrinogen, Factor VIII, Factor XIII, and von Willebrand factor. The target is to keep fibrinogen above 100-150 mg/dL.

• FFP is given for broad factor replacement when PT and aPTT are prolonged. It is less concentrated than cryoprecipitate for fibrinogen but provides a wider range of clotting factors.

• Platelet transfusion is given if platelets are below 50,000/microL and the patient is bleeding, or below 10,000-20,000/microL even prophylactically.

An important exam trap: Do NOT withhold blood products out of fear that you are "fueling the fire" of DIC. This is an outdated concept. Current guidelines support transfusion in bleeding DIC patients. The consumed factors need to be replaced while the underlying cause is being treated.

Heparin is the most commonly tested therapeutic controversy in DIC. The key rule: heparin is used only in chronic, thrombosis-predominant DIC (e.g., Trousseau syndrome from malignancy, purpura fulminans). It is generally avoided in acute hemorrhagic DIC because it worsens bleeding. However, if the vignette describes a patient with DIC who has predominant thrombosis (e.g., acral ischemia, DVT, or Trousseau syndrome) rather than bleeding, heparin becomes the correct answer.

Antifibrinolytics (tranexamic acid, aminocaproic acid) are a well-known contraindication in DIC. The rationale: fibrinolysis in DIC is actually a protective response that breaks down the dangerous microthrombi. Blocking fibrinolysis allows microthrombi to persist and worsen organ failure. The only narrow exception is life-threatening hemorrhage refractory to all other therapies, and even then it remains controversial.

ATRA in APL-associated DIC is a critical, commonly tested concept. APL (acute promyelocytic leukemia, defined by the t(15;17) translocation and PML-RARA fusion gene) causes DIC through the release of procoagulant granules from leukemic promyelocytes. ATRA induces differentiation of these cells and is the definitive treatment for both the leukemia and the DIC. This is one of the few situations where DIC resolves with treatment of the underlying malignancy alone.

05Differential Diagnosis and Distractors

The single most tested differentiation is DIC vs. TTP/HUS. All three produce thrombocytopenia and schistocytes. The discriminator is: check the PT/aPTT and fibrinogen. If PT/aPTT are prolonged and fibrinogen is low, it is DIC. If PT/aPTT and fibrinogen are normal, it is TTP or HUS.

06Traps and High-Yield Pearls

The most common way students get DIC questions wrong is by failing to recognize it as a secondary process and instead treating it as a primary diagnosis. Every DIC vignette will contain an embedded trigger. If you see prolonged PT/aPTT, low platelets, low fibrinogen, and elevated D-dimer, the next step is not to simply "diagnose DIC" but to identify and treat the underlying cause. The question may ask "what is the next best step in management?" and the correct answer will almost always be treating the trigger (e.g., start IV antibiotics for sepsis, emergent cesarean delivery for abruption, initiate ATRA for APL), not ordering more labs or transfusing blood products in isolation.

A second common trap involves confusing DIC with TTP. Both produce schistocytes and thrombocytopenia, and both can cause renal and neurologic dysfunction. Students who anchor on "schistocytes = TTP" will miss DIC. The discriminator to hardwire: check the coagulation studies. DIC consumes everything (factors, fibrinogen, and platelets), so PT/aPTT are prolonged and fibrinogen is low. TTP only consumes platelets, so PT/aPTT and fibrinogen remain normal.

A third trap is the heparin question. A vignette may describe DIC with predominant thrombosis (e.g., digital gangrene, Trousseau syndrome) and ask about management. Students reflexively avoid heparin because "DIC = bleeding," but in thrombosis-predominant DIC, heparin is correct. The key is reading the clinical picture carefully: if thrombosis dominates, anticoagulate. If hemorrhage dominates, transfuse.

Finally, remember the antifibrinolytic contraindication. If a question offers tranexamic acid or aminocaproic acid as a treatment option for DIC, it is almost always the wrong answer. The examiner is testing whether you understand that fibrinolysis is protective in DIC and that blocking it worsens organ damage.

The core competency being tested across all DIC questions is the ability to recognize a consumptive coagulopathy in a critically ill patient, distinguish it from other causes of thrombocytopenia and microangiopathy, and prioritize treatment of the underlying cause above all supportive measures.